Smith Stan 4
4 · MAIA Biotechnology, Inc. · Filed Apr 2, 2026
Research Summary
AI-generated summary of this filing
MAIA Director Stan Smith Receives 33,099 Option Award
What Happened
- Stan Smith, a director of MAIA Biotechnology, Inc. (MAIA), received a grant of 33,099 derivative securities (stock options) on March 31, 2026. The Form 4 shows an acquisition price of $0.00 for the award (common reporting for option grants). The options vest 100% on the grant date and are exercisable as of that date.
Key Details
- Transaction date: 2026-03-31; Form 4 filed: 2026-04-02 (appears timely).
- Award: 33,099 stock options; filing lists acquisition price $0.00 (derivative award).
- Vesting/exercise: Options vest 100% on grant date and are immediately exercisable (Footnote F1).
- Beneficial ownership: Securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993 (Footnote F2).
- Shares owned after transaction: Not specified in the filing.
Context
- This was an equity award (grant of options), not a purchase or sale of shares. Because the options vest immediately and are exercisable, Mr. Smith could choose to exercise them, which would be reported separately if/when exercised or sold. Grants are routine compensation for insiders and do not by themselves indicate a purchase or sale sentiment.
Insider Transaction Report
Form 4
Smith Stan
Director
Transactions
- Award
Stock Options
[F1][F2]2026-03-31+33,099→ 33,099 total(indirect: See footnote)Exercise: $1.40From: 2026-03-31Exp: 2036-03-31→ Common Stock (33,099 underlying)
Footnotes (2)
- [F1]The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
- [F2]These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Signature
/s/ Stan V. Smith|2026-04-02